Live Breaking News & Updates on Antitumor Activity

Stay updated with breaking news from Antitumor activity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Region Flamande , Soult Ukpyolsi , South Korea , United States , Republic Of Korea , Byoung Chul Cho , Henar Hevia , Craig Tendler , American Lung Association , Slate Development , Janssen Cilag International , American Society Of Clinical Oncology , European Medicines Agency Seeking Approval , Janssen Cilag International Nv Inc , Committee For Medicinal Products Human Use , National Cancer Institute , European Society For Medical Oncology , Exchange Commission , None Of Janssen Cilag International , European Medicines Agency , Yonsei University College Of Medicine , Global Medical Affairs , American Society For Clinical Oncology Annual Meeting , European Commission , Clinical Oncology , Annual Meeting ,

Johnson & Johnson receives positive CHMP opinion for

This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of. ....

France General , Region Flamande , United States , Nicolas Girard , Henar Hevia , Institut Curie , Paris Saclay University , European Medicines Agency , European Society For Medical Oncology Congress , Exchange Commission , European Union , American Lung Association , Janssen Biotech Inc , European Medicines Agency Seeking Approval , European Commission , Committee For Medicinal Products Human Use , Janssen Cilag International , Janssen Research Development , Medicinal Products , Human Use , Professor Nicolas Girard , Medical Oncology , Thoracic Oncology , Respiratory Medicine , Senior Director , Area Lead ,

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembr ....

United States , Joyce Allaire , Merck Co , Merck Sharp Dohme Corp , Exchange Commission , Merck Co Inc , Stephen Hurly , Chief Executive Officer , Chief Scientific Officer , Merck Sharp , Dohme Corp , Sci Advisors , Prostate Cancer , Merck Co , Prostate Specific Membrane Antigen , Dose Escalation , Cancer Cells , Tumor Cells , Antitumor Activity ,

Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST

News Release

Media Contacts:

Zayn Qureshi

+44 7760 334666 Email: zqureshi@its.jnj.com

Investor. ....

Region Flamande , United States , Catherine Taylor , Kiran Patel , Zayn Qureshi , Janssen Research Development , Janssen Biotech Inc , European Union , Janssen Pharmaceutical Companies Of Johnson , Clinical Development , National Cancer Institute , American Lung Association , European Society Of Medical Oncology , Janssen Research , European Medicines Agency , Cilag Gmbh International , Agency Seeking Approval Of Lazertinib , European Commission , Exchange Commission , European Society For Medical Oncology , Companies Of Johnson , Yuhan Corporation , News Release , Submits Marketing Authorisation Application , European Medicines , Seeking Approval ,

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and. ....

United States , France General , United Kingdom , New York , Pierre Louis Germain , Christophe Le Tourneau , Brandon Owens , Louis Kayitalire , Ligia Vela Reid , Exchange Commission , Given The Company , Drug Administration , Investor Relations Department , University Of Texas Md Anderson Cancer Center , French Financial Markets Authority Autorit , European Society For Medical Oncology , Communications Department , Strategic Collaborator Presented Phase , Overall Survival , All Patients Treated , Objective Response , Progression Free Survival , European Society , Medical Oncology , Endoscopic Ultrasound , Locally Advanced ,